In-vivo and in-vitro diagnostics in molecular medicine

In molecular medicine - and particularly in oncology - Siemens Medical Solutions is concentrating on further development of the FDG (fluorodeoxyglucose) biomarker to improve identification of certain tumours.

Photo: In-vivo and in-vitro diagnostics in molecular medicine

Thanks to the combination of in-vivo and in-vitro diagnostic procedures, the relatively unspecific image currently delivered by the FDG marker can be combined with additional information from laboratory diagnostics and interpreted accordingly. In turn, the results deliver clues to further development of specific markers.
It is also conceivable that there will be more fine-tuning in the development of in-vivo and in-vitro biomarkers, so that disease patterns that are localised in-vitro can be specified with the appropriate in-vivo biomarkers. Both areas are still so innovative that, as yet, there are no tangible synergies. However, the potential for an integrated diagnostics company is great, seeing how the trend points towards a combination of early, localised detection with radioactive biomarkers in in-vivo diagnostics with fluorescent markers matched in detailed in-vitro diagnostics.


Read all latest stories

Related articles


Improvement of cardiac care

Rapid myocardial infarction verification

The use of troponin assays to rule in or rule out myocardial infarction (MI) rapidly is critical on several levels. The quick result can reassure the patient that they have not had a heart attack and…



AI helpers simplify clinical MRI scans

The new 1.5 Tesla MRI from Siemens Healthineers, Magnetom Sola, is packed with helpful algorithms and other functions. AI-supported systems monitor patients and scan parameters and ensure consistent…


Lab equipment

It takes a team

Clinical laboratories need to meet greater testing demands, improve efficiency, and deliver reliable, high-quality results, while at the same time, facing an increasing shortage of skilled employees…

Related products